Evidence map›Paper›PMID 26728587›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2016

Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.

Valvanera Fernández-Laso, Cristina Sastre, Jose M Valdivielso, Angels Betriu, Elvira Fernández, Jesús Egido, Jose L Martín-Ventura, Luis M Blanco-Colio

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Valvanera Fernández-LasoVascular Research Laboratory, Fundación Jiménez Díaz University Hospital-Health Research Institute, Madrid, Spain; and.
Cristina SastreVascular Research Laboratory, Fundación Jiménez Díaz University Hospital-Health Research Institute, Madrid, Spain; and.
Jose M ValdivielsoUnit for Detection and Treatment of Atherothrombotic Diseases, Experimental Nephrology Laboratory, Arnau de Vilanova University Hospital, Biomedical Research Institute of Lleida, Lleida, Spain.
Angels BetriuUnit for Detection and Treatment of Atherothrombotic Diseases, Experimental Nephrology Laboratory, Arnau de Vilanova University Hospital, Biomedical Research Institute of Lleida, Lleida, Spain.
Elvira FernándezUnit for Detection and Treatment of Atherothrombotic Diseases, Experimental Nephrology Laboratory, Arnau de Vilanova University Hospital, Biomedical Research Institute of Lleida, Lleida, Spain.
Jesús EgidoVascular Research Laboratory, Fundación Jiménez Díaz University Hospital-Health Research Institute, Madrid, Spain; and.
Jose L Martín-VenturaVascular Research Laboratory, Fundación Jiménez Díaz University Hospital-Health Research Institute, Madrid, Spain; and.
Luis M Blanco-ColioVascular Research Laboratory, Fundación Jiménez Díaz University Hospital-Health Research Institute, Madrid, Spain; and lblanco@fjd.es.
Hospital Universitario Fundación Jiménez Díaz · ESInstituto de Investigación Biomédica de Lleida · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesSoluble TNF-like weak inducer of apoptosis (sTWEAK) is a proinflammatory cytokine belonging to the TNF superfamily. sTWEAK concentrations have been associated with the presence of CKD and cardiovascular disease (CVD). We hypothesized that sTWEAK levels may relate to a higher prevalence of atherosclerotic plaques, vascular calcification, and cardiovascular outcomes observed in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A 4-year prospective, multicenter, longitudinal study was conducted in 1058 patients with CKD stages 3-5D (mean age =58±13 years old; 665 men) but without any history of CVD from the NEFRONA Study (a study design on the prevalence of surrogate markers of CVD). Ankle-brachial index and B-mode ultrasound were performed to detect the presence of carotid and/or femoral atherosclerotic plaques together with biochemical measurements and sTWEAK assessment. Patients were followed for cardiovascular outcomes (follow-up of 3.13±1.15 years).

resultsPatients with more advanced CKD had lower sTWEAK levels. sTWEAK concentrations were independently and negatively associated with carotid intima-media thickness. sTWEAK levels were lower in patients with carotid atherosclerotic plaques but not in those with femoral plaques. After adjustment by confounders, the odds ratio (OR) for presenting carotid atherosclerotic plaques in patients in the lowest versus highest tertile of sTWEAK was 4.18 (95% confidence interval [95% CI], 2.89 to 6.08; P<0.001). Furthermore, sTWEAK levels were lower in patients with calcified carotid atherosclerotic plaques. The OR for presenting calcified carotid plaques was 1.77 (95% CI, 1.06 to 2.93; P=0.02) after multivariable adjustment. After the follow-up, 41 fatal and 68 nonfatal cardiovascular events occurred. In a Cox model, after controlling for potential confounding factors, patients in the lowest tertile of sTWEAK concentrations had a higher risk of fatal and nonfatal cardiovascular events (hazard ratio [HR], 2.40; 95% CI, 1.33 to 4.33; P=0.004) and cardiovascular mortality (HR, 2.67; 95% CI, 1.05 to 6.76; P=0.04).

conclusionsLow sTWEAK levels were associated with the presence of carotid atherosclerotic plaques in patients with CKD. Additionally, lower sTWEAK levels were associated with a higher risk of cardiovascular morbidity and mortality.

Indexed as

Femoral ArteryAgedAnkle Brachial IndexBiomarkersCarotid Artery DiseasesCarotid Intima-Media ThicknessChi-Square DistributionCytokine TWEAKDown-RegulationFemaleHumansLogistic ModelsLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisBiomarkersCytokine TWEAKTNFSF12 protein, humanTumor Necrosis Factorsankle brachial indexcardiovascular diseasecarotid intima-media thicknesschronic kidney diseasecytokineshumansoutcomesprospective studiesrenal insufficiency, chronicsTWEAKtumor necrosis factors

Identifiers

PMID26728587
PMCPMC4791813
OpenAlexW2273201359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.